Abstracts tagged "heart block and neonatal lupus"

Abstract Number: 924 • 2018 ACR/ARHP Annual Meeting
10X Genomics-Based Single-Cell RNA-Seq and Low Input RNA-Seq Identify a Transcriptional Landscape Supporting Interferon in the Pathogenesis of Autoimmune-Associated Congenital Heart Block
Hemant Suryawanshi¹, Jill P. Buyon², Miao Chang², Thomas Tuschl¹ and Robert M. Clancy², ¹Howard Hughes Medical Institute and The Rockefeller University, New York, NY, ²NYU School of Medicine, New York, NY
Background/Purpose: Towards understanding the molecular mechanisms that link maternal anti-Ro antibodies to the development of conduction system disease in a second trimester fetus, single cell…
Abstract Number: 1827 • 2014 ACR/ARHP Annual Meeting
Anti-Ro and Anti-La Antibodies in the General Pregnant Population
Evelyn V. Rozenblyum¹, Sharon Sukhdeo², Edgar Jaeggi³, Lisa Hornberger⁴, Philip Wyatt⁵, Carl A. Laskin⁶ and Earl D. Silverman⁷, ¹Pediatrics, University of Toronto, Toronto, ON, Canada, ²Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ³Cardiology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁴Pediatric Cardiology , Tel: 780-407-3355; Fax: 780-407-3954;, Stollery Children's Hospital, Edmonton, ON, Canada, ⁵Department of Genetics, North York General Hospital, Toronto, ON, Canada, ⁶University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose Neonatal lupus erythematosus (NLE) is a passively transferred autoimmune disease that occurs in babies born to pregnant women with anti-Ro and anti-La antibodies. The…
Abstract Number: 534 • 2014 ACR/ARHP Annual Meeting
Serum Biomarkers of Inflammation and Fibrosis in Advancing Diagnosis, Prognosis and Treatment of Anti-Ro Associated Congenital Heart Block
Amit Saxena¹, Peter M. Izmirly², Sung Won Han³, Andrew Markham⁴, Robert M. Clancy⁵ and Jill P. Buyon⁵, ¹Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Department of Population Health, New York University School of Medicine, New York, NY, ⁴Medicine, New York University School of Medicine, New York, NY, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose Women with Sjogren’s Syndrome (SS) and anti-Ro antibodies face the risk of a pregnancy complicated by fetal congenital heart block (CHB). Identification of maternal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].